[1]
|
Li, Y., Teng, D., Shi, X., et al. (2020) Prevalence of Diabetes Recorded in Mainland China Using 2018 Diagnostic Crite-ria from the American Diabetes Association: National Cross Sectional Study. BMJ, 369, m997.
https://doi.org/10.1136/bmj.m997
|
[2]
|
Zhang, L., Long, J., Jiang, W., et al. (2016) Trends in Chronic Kidney Dis-ease in China. The New England Journal of Medicine, 375, 905-906. https://doi.org/10.1056/NEJMc1602469
|
[3]
|
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020) KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 98, S1-S115.
https://doi.org/10.1016/j.kint.2020.06.019
|
[4]
|
高翔, 梅长林. 《慢性肾脏病早期筛查、诊断及防治指南(2022年版)》解读[J]. 中国实用内科杂志, 2022, 42(9): 735-739
|
[5]
|
李焱. 胰岛素的过去、现在和未来——胰岛素的意义, 从生理到病理[J]. 中国医学前沿杂志(电子版), 2021, 13(6): 9-15.
|
[6]
|
中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南(2021年版) [J]. 中华糖尿病杂志, 2021, 13(8): 762-784.
|
[7]
|
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版) [J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
|
[8]
|
戴冬君, 陆静毅, 周健. 持续葡萄糖监测新指标: 葡萄糖在目标范围内时间的临床意义解析[J]. 中华糖尿病杂志, 2019(2): 139-140.
|
[9]
|
杨剑. 西格列汀对常规降糖效果不佳2型糖尿病患者的治疗作用[J]. 中华临床医师杂志(电子版), 2016, 10(4): 596-598.
|
[10]
|
宁光, 王卫庆. 格列喹酮临床应用中国专家共识(2017年版) [J]. 中华内分泌代谢杂志, 2017, 33(5): 363-366.
|
[11]
|
母义明, 杨文英, 朱大龙, 等. 磺脲类药物临床应用专家共识(2016年版) [J]. 药品评价, 2017, 14(1): 5-12.
|
[12]
|
陈頔, 刘治军. 不同格列奈类药物的药代动力学比较[J]. 药品评价, 2015, 12(13): 12-15.
|
[13]
|
殷琦, 李鹏, 郭理博, 李可欣, 孙春华. 那格列奈的药理特性与临床应用[J]. 中国医院用药评价与分析, 2004(4): 249-251.
|
[14]
|
陈镇涛, 王苓. 吡格列酮联合二甲双胍对2型糖尿病患者胰岛素抵抗及炎性因子的影响[J]. 广东医科大学学报, 2018, 36(2): 138-140.
|
[15]
|
Zhao, X.-Y., Wang, H.-G., Zhou, Q.-M., He, P. and Du, G.-H. (2018) Research Progress on Pharmacological Effect and Mechanism of Baicalein in Parkinson Diseases. Chinese Jour-nal of Pharmacology and Toxicology, 32, 341-342.
|
[16]
|
董慧, 田坚, 张盈妍, 等. 沙格列汀联合二甲双胍治疗2型糖尿病伴非酒精性脂肪肝的临床效果[J]. 广西医学, 2017, 39(3): 316-318.
|
[17]
|
母义明, 纪立农, 宁光, 等. 二甲双胍临床应用专家共识(2018年版) [J]. 药品评价, 2019, 16(5): 3-15.
|
[18]
|
中华医学会临床药学分会. 2型糖尿病合并慢性肾脏病患者多重用药安全中国专家共识[J]. 中国全科医学, 2022, 25(23): 2819-2835.
|
[19]
|
李珍, 宋洪杰, 唐世新, 计一平, 刘涛. 盐酸吡格列酮片的人体药代动力学研究[J]. 中国临床药理学杂志, 2002(5): 368-370.
|
[20]
|
谌贻璞. 糖尿病合并慢性肾功能不全患者血糖管理的特殊要求[J]. 中国实用内科杂志, 2015, 35(6): 503-505.
|
[21]
|
张艳秀, 蔡乐, 赵佳慧, 程庆砾. 重视肾功能不全老年患者的临床合理用药[J]. 中国临床保健杂志, 2021, 24(5): 582-588.
|
[22]
|
杨静静, 黄帅, 吴倩, 等. 胰高血糖素样肽-1受体激动剂治疗肥胖的研究进展[J]. 临床荟萃, 2022, 37(5): 477-480.
|
[23]
|
Hanefeld, M., Arteaga, J.M., Leiter, L.A., et al. (2017) Efficacy and Safety of Lixisenatide in Patients with Type 2 Diabetes and Renal Impairment. Diabetes, Obesity and Metabolism, 19, 1594-1601. https://doi.org/10.1111/dom.12986
|
[24]
|
Davies, M.J., Bain, S.C., Atkin, S.L., et al. (2016) Efficacy and Safety of Liraglutide versus Placebo as Add-On to Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care, 39, 222-230. https://doi.org/10.2337/dc14-2883
|
[25]
|
Idorn, T., Knop, F.K., Jorgensen, M.B., et al. (2016) Safety and Efficacy of Liraglutide in Patients with Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care, 39, 206-213. https://doi.org/10.2337/dc15-1025
|
[26]
|
代雪飞, 杜娟. 钠-葡萄糖共转运蛋白2抑制剂降糖及降糖外作用研究进展[J]. 实用药物与临床, 2022, 25(10): 929-933.
|
[27]
|
Macha, S., Mattheus, M., Halabi, A., et al. (2014) Pharmaco-kinetics, Pharmacodynamics and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Sub-jects with Renal Impairment. Diabetes, Obesity and Metabolism, 16, 215-222. https://doi.org/10.1111/dom.12182
|
[28]
|
Barnett, A.H., Mithal, A., Manassie, J., et al. (2014) Efficacy and Safety of Empagliflozin Added to Existing Antidiabetes Treatment in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Diabetes & Endocrinology, 2, 369-384.
https://doi.org/10.1016/S2213-8587(13)70208-0
|
[29]
|
刘芳, 赵鸿燕, 谢永红, 等. 奥格列汀: 治疗2型糖尿病的新型长效二肽基肽酶4抑制剂[J]. 中国新药与临床杂志, 2016, 35(10): 694-698.
|
[30]
|
Friedrich, C., Emser, A., Woerle, H.J., et al. (2013) Renal Impairment Has No Clinically Relevant Effect on the Long-Term Exposure of Linagliptin in Patients with Type 2 Diabetes. American Journal of Therapeutics, 20, 618-621.
https://doi.org/10.1097/MJT.0b013e31826232dc
|
[31]
|
李春杏, 纪立伟. 5种DPP-4抑制剂分子结构差异及药代动力学特性[J]. 药品评价, 2019, 16(8): 3-9.
|
[32]
|
余学锋. 胰岛素的过去、现在和未来——胰岛素制剂发展与应用[J]. 中国医学前沿杂志(电子版), 2021, 13(6): 4-8.
|
[33]
|
Singhsakul, A., Supasyndh, O. and Satirapoj, B. (2019) Effectiveness of Dose Adjustment of Insulin in Type 2 Diabetes among Hemodialysis Patients with End-Stage Renal Disease: A Randomized Crossover Study. Journal of Diabetes Research, 2019, Article ID: 6923543. https://doi.org/10.1155/2019/6923543
|
[34]
|
Roussel, R., Lorraine, J., Rodriguez, A., et al. (2015) Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. Advances in Therapy, 32, 1029-1064.
https://doi.org/10.1007/s12325-015-0261-x
|
[35]
|
Agarwal, M.M., Punnose, J., Sukhija, K., et al. (2018) Gestational Diabetes Mellitus: Using the Fasting Plasma Glucose Level to Simplify the International Association of Diabetes and Pregnancy Study Groups Diagnostic Algorithm in an Adult South Asian Population. Canadian Journal of Diabetes, 42, 500-504.
https://doi.org/10.1016/j.jcjd.2017.12.009
|
[36]
|
李洪梅, 朱海清. 中国糖尿病肾脏病防治指南(2021年版)解读[J]. 中国医刊, 2022, 57(2): 133-138.
|
[37]
|
朱启磊, 王英丽. 慢性肾脏病合并2型糖尿病患者降糖药物应用现状分析[J]. 中国现代药物应用, 2022, 16(7): 164-167.
|
[38]
|
国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2021年版) [J]. 中华糖尿病杂志, 2021, 13(1): 14-46.
|